Literature DB >> 7271269

Human pharmacokinetics and disposition of sarmoxicillin, a lipophilic amoxicillin prodrug.

R D Smyth, M Pfeffer, D R Van Harken, A Cohen, G H Hottendorf.   

Abstract

Sarmoxicillin, an amoxicillin prodrug, is the methoxymethyl ester of hetamoxicillin. Esterification converted amoxicillin from an amphoteric to a cationic compound and resulted in a 30- to 600-fold increase in lipid partitioning. Oral absorption studies in normal subjects demonstrated that sarmoxicillin was only partially hydrolyzed by nonenzymatic and gut or hepatic first-pass metabolism and that significant quantities of intact ester appeared in the systemic circulation. Sarmoxicillin was converted to amoxicillin in plasma by hydrolysis of the acetone penicinate and the methoxymethyl ester bonds. Significant amoxicillin levels were demonstrated in saliva after administration of sarmoxicillin, but not amoxicillin, over a 250- to 1,000-mg dose range. Differences in the absorption, distribution, or metabolism of amoxicillin were also evident in the lower plasma amoxicillin maximum concentration and area under the curve and longer half-life after sarmoxicillin administration. Differences in the distribution of this lipophilic ester could result in a significant increase in tissue penetration and subsequent therapeutic efficacy of amoxicillin when administered as sarmoxicillin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7271269      PMCID: PMC181599          DOI: 10.1128/AAC.19.6.1004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  On the distribution of drugs in saliva and blood plasma.

Authors:  K Feller; G le Petit
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-10

2.  Absorption of bacampicillin and ampicillin and penetration into body fluids (skin blister fluid, saliva, tears) in healthy volunteers.

Authors:  C Simon; V Malerczyk; M Klaus
Journal:  Scand J Infect Dis Suppl       Date:  1978

3.  Bioavailability of talampicillin.

Authors:  K H Jones
Journal:  Br Med J       Date:  1977-07-23

4.  Amoxycillin levels in sputum, serum, and saliva.

Authors:  S M Stewart; I M Anderson; G R Jones; M A Calder
Journal:  Thorax       Date:  1974-01       Impact factor: 9.139

5.  Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects.

Authors:  W J Jusko; G P Lewis; G W Schmitt
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

6.  Prostatic fluid and tissue concentrations of ampicillin after administration of hetacillin ester (BL-P1761).

Authors:  T B Kjaer; P O Madsen
Journal:  Invest Urol       Date:  1976-07

7.  Rapid determination of amoxycillin (clamoxyl) and ampicillin (penbritin) in body fluids of many by means of high-performance liquid chromatography.

Authors:  T B Vree; Y A Hekster; A M Baars; E Van der Kleijn
Journal:  J Chromatogr       Date:  1978-05-01

8.  Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration.

Authors:  D A Spyker; R J Rugloski; R L Vann; W M O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

9.  Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man.

Authors:  M Ehrnebo; S O Nilsson; L O Boréus
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

10.  Pharmacokinetics of ampicillin and methoxymethyl ester of hetacillin in dogs.

Authors:  T B Kjaer; P G Welling; P O Madsen
Journal:  J Pharm Sci       Date:  1977-03       Impact factor: 3.534

View more
  2 in total

1.  Amoxicillin concentrations in nasal secretions of patients with acute uncomplicated sinusitis and in paranasal sinus mucosa of patients with chronic sinusitis.

Authors:  G Kment; A Georgopoulos; W Ridl; J Mühlbacher
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

Review 2.  Antibacterial Prodrugs to Overcome Bacterial Resistance.

Authors:  Buthaina Jubeh; Zeinab Breijyeh; Rafik Karaman
Journal:  Molecules       Date:  2020-03-28       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.